Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401665 | 0.77 | NISCH (0.48) | NISCHCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL14543303 | 0.77 | NISCH (0.48) | NISCHCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL8347684 | 0.77 | NISCH (0.48) | NISCHCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL266615 | 0.77 | NISCH (0.48) | NISCHCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL28474359 | 0.73 | NISCH (0.46) | NISCHPOLBESR2MTNR1ALTA4H | |
| SCHEMBL1079302 | 0.72 | NISCH (0.48) | NISCHCHRNB4CHRNA3TDP1KMT2A | |
| SCHEMBL1567701 | 0.70 | NISCH (0.50) | NISCHCHRNB4CHRNA3TDP1KMT2A | |
| SCHEMBL28894086 | 0.69 | POLB (0.46) | NISCHCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3809469 | 0.69 | POLB (0.46) | NISCHCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL15127606 | 0.69 | ABCG2 (0.50) | NISCHCHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | NISCH 305/4885CHRNB4 221/4885CHRNA3 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.